BRCAness and prostate cancer: diagnostic and therapeutic considerations

Keyphrases

• Prostate Cancer Screening 100%
• Genome Sequencing 100%
• PARP Inhibitor (PARPi) 100%
• Cancer Therapeutics 100%
• Therapeutic Considerations 100%
• Diagnostic Considerations 100%
• BRCAness 100%
• Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 66%
• DNA Repair 66%
• Prostate Cancer 33%
• Circulating Tumor Cells 33%
• Clinical Course 33%
• Carboplatin 33%
• Therapeutic Strategies 33%
• Treatment Decisions 33%
• Gene mutation 33%
• Resistance Mechanisms 33%
• Metastatic Castration-resistant Prostate Cancer (mCRPC) 33%
• Cell-free DNA (cfDNA) 33%
• Recent Advances 33%
• DNA Detection 33%
• Patients with Prostate Cancer 33%
• DNA Repair Genes 33%
• Diagnostic Approach 33%
• DNA Assay 33%
• Cell-based Assay 33%
• Further Treatment 33%
• Germline Genetics 33%
• Cell-free DNA Screening 33%
• Tumor Genomics 33%
• Germline Genetic Testing 33%
• Reversion mutation 33%

Medicine and Dentistry

• Prostate Cancer 100%
• Cancer Diagnostics 100%
• PARP Inhibitor 50%
• DNA Repair 50%
• Somatics 33%
• Cell-Free DNA 33%
• Germ Cell 33%
• Circulating Tumor Cell 16%
• Neoplasm 16%
• Carboplatin 16%
• Prevalence 16%
• Disease Course 16%
• Gene Mutation 16%
• Genome Sequencing 16%
• DNA Sequencing 16%
• Revertant 16%